Barclays’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.68M | Buy |
313,824
+58,212
| +23% | +$1.24M | ﹤0.01% | 1404 |
|
|
2025
Q1 | $4.93M | Sell |
255,612
-74,534
| -23% | -$1.44M | ﹤0.01% | 1435 |
|
|
2024
Q4 | $5.89M | Buy |
330,146
+80,028
| +32% | +$1.43M | ﹤0.01% | 1462 |
|
|
2024
Q3 | $5.48M | Sell |
250,118
-137,195
| -35% | -$3M | ﹤0.01% | 1468 |
|
|
2024
Q2 | $3.02M | Sell |
387,313
-5,999
| -2% | -$46.8K | ﹤0.01% | 1438 |
|
|
2024
Q1 | $1.63M | Buy |
393,312
+74,747
| +23% | +$309K | ﹤0.01% | 2083 |
|
|
2023
Q4 | $831K | Buy |
318,565
+170,549
| +115% | +$445K | ﹤0.01% | 2732 |
|
|
2023
Q3 | $277K | Buy |
148,016
+99,744
| +207% | +$187K | ﹤0.01% | 2865 |
|
|
2023
Q2 | $120K | Sell |
48,272
-198,192
| -80% | -$493K | ﹤0.01% | 3333 |
|
|
2023
Q1 | $432K | Buy |
246,464
+232,605
| +1,678% | +$408K | ﹤0.01% | 2734 |
|
|
2022
Q4 | $59K | Buy |
13,859
+11,770
| +563% | +$50.1K | ﹤0.01% | 3720 |
|
|
2022
Q3 | $2K | Buy |
2,089
+961
| +85% | +$920 | ﹤0.01% | 4513 |
|
|
2022
Q2 | $1K | Sell |
1,128
-3,233
| -74% | -$2.87K | ﹤0.01% | 4641 |
|
|
2022
Q1 | $11K | Buy |
+4,361
| New | +$11K | ﹤0.01% | 4471 |
|